Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 587-592

  Xu, Gaosi ^a   Tu, Weiping ^a   Xu, Chengyun ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Exit site infection; Mupirocin; Peritoneal dialysis; Peritonitis

Indexed keywords

PLACEBO; PSEUDOMONIC ACID;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PERITONITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; INFECTION RATE; INFECTION RISK; META ANALYSIS; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PUNCTURE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COHORT STUDIES; HUMANS; MUPIROCIN; PERITONEAL DIALYSIS; PERITONITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 75649146258     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp411     Document Type: Article

References (28)

1. Fried L, Abidi S, Bernardini J et al. Hospitalization in peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 927-933
2. Bernardini J, Bender F, Florio T et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16: 539-545
3. Piraino B, Bernardini J, Florio T et al. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23: 456-459
4. Thodis E, Bhaskaran S, Pasadakis P et al. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18: 261-270
5. Piraino B, Bailie GR, Bernardini J et al. ISPD guidelines/ recommendations. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-131
6. Mujais S. Microbiology and outcomes of peritonitisin NorthAmerica. Kidney Int Suppl 2006; 70: S55-S62
7. Prasad N, Gupta A. Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2005; 25: 207-222
8. Williams JD, Davies SJ. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney, 2nd edn. London: Saunders, 2003
9. Annigeri R, Conly J, Vas S et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21: 554-559
10. Lobbedez T, Gardam M, Dedier H et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years. Nephrol Dial Transplant 2004; 19: 3140-3143
11. Miller MA, Dascal A, Portnoy J et al. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-813
12. Tacconelli E, Carmeli Y, Aizer A et al. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003; 37: 1629-1638
13. Strippoli GF, TongA,Johnson Det al. Antimicrobial agentsto prevent peritonitis in peritoneal dialysis: a systemic review of randomized controlled trials. Am J Kidney Dis 2004; 44: 591-603
14. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
15. Sit D, Kadiroglu AK, Kayabasi H et al. Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients. Adv Ther 2007; 24: 387-393
16. Mahajan S, Tiwari SC, Kalra V et al. Effect of local mupirocin application on exit-site infection and peritonitis in an India peritoneal dialysis population. Perit Dial Int 2005; 25: 473-477
17. Uttley L, Vardhan A, Mahajan S et al. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site. J Nephrol 2004; 17: 242-245
18. Zeybel M, Ozder A, Sanlidag C et al. The effects of weekly mupirocin application on infections in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19: 198-201
19. Wong SSH, Chu KH, Cheuk A et al. Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis by applying mupirocin ointment at the catheter exit site. Perit Dial I nt 2003; 23(Suppl 2): S153-S158
20. Thodis E, Passadakis P, Panagoutsos S et al. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Adv Perit Dial 2000; 16: 257-261
21. Casey M, Taylor J, Clinard P et al. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20: 566-574
22. Crabtree JH, Hadnott LL, Burchette RJ et al. Outcome and clinical implications of a surveillance and treatment program for Staphylo-coccus aureus nasal carriage in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 271-275
23. Mylotte JM, Kahler L, Jackson E. 'Pulse' nasal mupirocin maintenance regimen in patients undergoing continuous ambulatory peritoneal dialysis. Infect Control Hosp Epidemiol 1999; 20: 741-745
24. Davey P, Craig AM, Hau C et al. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on randomized, placebo-controlled trial. J Antimicrob Chemother 1999; 43: 105-112
25. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996; 7: 2403-2408
26. Perez-Fontan M, Garcia-Falcon T, Rosales M. Treatment of Staphy-lococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22: 708-712
27. Cavdar C, Saglam F, Sifil A et al. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. Ren Fail 2008; 30: 417-422
28. Perez-Fontan M, Rosales M, Rodriguez-Carman A et al. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-341